Citations

Clear

6 citation(s) found for "Koç, Yener".

The current state of training in pain medicine fellowships: An Association of Pain Program Directors ( APPD ) survey of program directors
Wahezi, Sayed , Caparó, Moorice , Choi, Heejung , Eshraghi, Yashar , Naeimi, Tahereh , Kohan, Lynn , Anițescu, Magdalena , Wright, Thelma , Przkora, Rene , Patel, Kiran V., Lamer, Tim J. , Moeschler, Susan M. , Yener, Ugur , Alerte, Jonathan, Grandhe, Radhika, Bautista, Alexander , Spektor, Boris , Noon, Kristen , Reddy, Rajiv , Osuagwu, Uzondu, Carpenter, A. Alden, Gerges, Frederic J., Murphy, Casey, Kim, Chong , Marshall, Cameron, Kirchen, Gwynne, Oryhan, Christine , Singh, Tejinder S. Swaran, Lubenow, Timothy R. , Sehgal, Nalini , Argoff, Charles E. , Gulati, Amit , Day, Miles, Sibai, Nabil, Dua, Anterpreet, Barad, Meredith , Singh, Tarun D. , Osuagwu, Uchechukwu Levi , Emerick, Trent D , Naeimi, Tahereh , Moeschler, Susan, Yener, Ugur , Bautista, Alexander , Reddy, Rajiv , Barad, Meredith J , Horn, Danielle Bodzin , Pritzlaff, Scott , Marshall, Cameron, Singh, Tejinder S. Swaran, Sayed, Dawood , Shaparin, Naum

Mayo Clinic

Pain Practice | March 30, 2024 | Volume: 24 | Issue: 7 | Pages: 895-903

10.1111/papr.13373 | PMID 38553945 Get It

Abstract Introduction The Accreditation Council for Graduate Medical Education (ACGME) approved the first pain medicine fellowship programs over three decades ago, designed around a pharmacological philosophy. Following that, there has been a rise in the transition of pain medicine education toward a multidisciplinary interventional model based on a tremendous surge of contemporaneous literature in these areas. This trend has created variability in clinical experience and education amongst accredited pain medicine programs with minimal literature evaluating the differences and commonalities in education and experience of different pain medicine fellowships through Program Director (PD) experiences. This study aims to gather insight from pain medicine fellowship program directors across the country to assess clinical and interventional training, providing valuable perspectives on the future of pain medicine education. Methods This study involved 56 PDs of ACGME‐accredited pain fellowship programs in the United States. The recruitment process included three phases: advanced notification, invitation, and follow‐up to maximize response rate. Participants completed a standard online questionnaire, covering various topics such as subcategory fields, online platforms for supplemental education, clinical experience, postgraduate practice success, and training adequacy. Results Surveys were completed by 39/56 (69%) standing members of the Association of Pain Program Directors (APPD). All PDs allowed fellows to participate in industry‐related and professional society‐related procedural workshops, with 59% encouraging these workshops. PDs emphasized the importance of integrity, professionalism, and diligence for long‐term success. Fifty‐four percent of PDs expressed the need for extension of fellowship training to avoid supplemental education by industry or pain/spine societies. Conclusion This study highlights the challenge of providing adequate training in all Pain Medicine subtopics within a 12‐month pain medicine fellowship. PDs suggest the need for additional training for fellows and discuss the importance of curriculum standardization.
Metastatic non-small cell lung cancer (NSCLC) and brain edema: a topographical and clinicopathological investigation utilizing deep learning-based artificial intelligence (DLBAI)
Yun, Jonathan , Kurker, Kristina P. , Kumar, Jeyan S. , Sutherland, Grant , Farzad, Faraz, Sukumar, Rohit , Yener, Ulaş, Patel, Sohil H. , Schiff, David , Lopes, Beatriz, Mut, Melike , Maragkos, Georgios Α. , Feng, Xue

Mayo Clinic

No container title available | January 19, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3851661/v1 Get It

Abstract Tumor-associated vasogenic brain edema is a well-known contributor of morbidity and mortality in patients with metastatic disease to the brain. It is widely accepted that brain metastases (BM) is associated with extensive edema and can cause increased symptomatology such as pain, neurologic deficit, and elevated intracranial pressure depending on extent and location. We present a proof-of-concept retrospective analysis utilizing DLBAI to segment and detect radiological and topographical patterns of peritumoral edema and assess for clinicopathological correlates in 84 patients with NSCLC and BM who underwent surgical resection and were not previously on steroids. We found that overall, tumors in all locations demonstrated a mean 10:1 edema to tumor ratio (ETR) and an occipital tumor location was associated with a significantly elevated ETR. Within our cohort there were no other factors that were significantly associated with ETR. This study demonstrates a proof-of-concept that DLBAI is an efficient and accurate method of radiographic analysis that can be applied to detect and potentially predict clinicopathological data and prognostic determinants. Clinically, we demonstrate that NSCLC is associated with significant peritumoral edema and that topographical factors may be associated with increased extent of edema.
Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the
Kharfan‐Dabaja, Mohamed A. , Ayala, Ernesto , Blaise, Didier , Itälä‐Remes, Maija , Forcade, Édouard , Rabitsch, Werner , Bulabois, Claude‐Eric , Grillo, Giovanni , Rambaldi, Alessandro , Fanin, Renato , Zallio, Francesco, Renzo, Nicola Di , Novis, Yana , McDonald, Andrew , Herrera, Concha , Nagler, Arnon , Ciceri, Fabio , Blaise, Didier , Rambaldi, Alessandro , Labopin, Myriam , Bazarbachi, Ali , Vydra, Jan , Bramanti, Stéfania , Schmid, Christoph , Busca, Alessandro , Zecca, Marco , Kröger, Nicolaus , Koç, Yener , Sanz, Jaime , Mohty, Mohamad

Mayo Clinic

HemaSphere | June 27, 2023 | Volume: 7 | Issue: 7 | Pages: e920

10.1097/hs9.0000000000000920 | PMID 37388926 Get It

Availability of haploidentical donors has broadened utilization of allogeneic hematopoietic cell transplantation (allo-HCT). Peripheral blood stem cells (PBSC) are being used with increased frequency in haploidentical allo-HCT. We evaluated extent of HLA disparity (2–3/8 versus 4/8 HLA antigen mismatches) on post-allograft outcomes when using T-cell replete PBSC from haploidentical donors for acute myeloid leukemia in first complete remission. Primary objectives entailed assessing cumulative incidence of grade 2–4 acute graft-versus-host disease (GVHD) and chronic GVHD (any grade). A total of 645 patients received a haploidentical allo-HCT from a donor with either 2–3 of 8 HLA antigen mismatches (n = 180) or with 4 of 8 HLA antigen mismatches (n = 465). Presence of 2–3 of 8 versus 4 of 8 HLA mismatches did not affect the incidence of acute GVHD (grade 2–4) and chronic GVHD (any grade). Overall survival (OS), leukemia-free survival (LFS) relapse incidence (RI), nonrelapse mortality and the composite endpoint of GVHD-free relapse-free survival were also similar among the groups. Pertaining to HLA-B leader matching effect, our analysis did not discern any difference in aforementioned post-allograft outcomes for this variable. However, in univariate analysis, absence of an antigen mismatch in HLA-DPB1 showed a trend for better OS. Notwithstanding inherent limitations associated with registry data, our results did not show an advantage of selecting a haploidentical donor with 2–3 of 8 HLA antigen mismatches over one with 4 of 8 HLA antigen mismatches when using PBSC as the cell source. Adverse cytogenetics remains a major adverse determinant of inferior OS and LFS and a higher RI. Using reduced-intensity conditioning yielded worse OS and LFS.
Significance of Degree of HLA Disparity When Using Haploidentical Donors with T-Replete PBSC and Post-Transplantation Cyclophosphamide (PTCy) in Acute Myeloid Leukemia (AML) in First Complete Hematologic Remission (CR1)
Kharfan‐Dabaja, Mohamed A. , Ayala, Ernesto , Blaise, Didier , Novis, Yana , McDonald, Andrew , Herrera, Concha , Forcade, Édouard , Ciceri, Fabio , Nagler, Arnon , Blaise, Didier , Labopin, Myriam , Bazarbachi, Ali , Koç, Yener , Vydra, Jan , Busca, Alessandro , Castagna, Luca , Bulabois, Claude‐Eric , Schmid, Christoph , Sanz, Jaime , Mohty, Mohamad

Mayo Clinic

Blood | November 23, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 3910-3910

10.1182/blood-2021-149651 Get It

Abstract Background: Haploidentical allogeneic hematopoietic cell transplantation (haplo) has expanded applicability of the procedure to patients for whom a suitable HLA compatible donor was not available in the past. A small multicenter retrospective study of 185 patients with hematologic malignancies who received a nonmyeloablative preparative regimen followed by infusion of bone marrow (BM) hematopoietic cells from haploidentical donors showed no significant association between the number of HLA mismatches (HLA-A, -B, -C, and -DRB1 combined) and risk of acute grade 2-4 graft-versus-host disease (GVHD) (hazard ratio [HR]=0.89; P=0.68 for 3-4 mismatches vs fewer antigen mismatches). This haploidentical transplant platform has certainly evolved. Nowadays, G-CSF mobilized peripheral blood stem cells (PBSC) are commonly used owing to its increased convenience vis-à-vis performing a BM harvest. Study population: Here, we evaluate post transplant outcomes when using haploidentical donors with T-replete PBSC and PTCy in AML in CR1. A total of 494 patients (4/8 HLA mismatch (group 1)=360, 2-3/8 HLA mismatch (group 2)=134) underwent the procedure at an EBMT participating center. The primary endpoints were cumulative incidences of grade 2-4 acute GVHD and chronic (all grades) GVHD. Secondary endpoints included cumulative incidence of relapse (RI), non-relapse mortality (NRM), leukemia-free (LFS) and overall survival (OS) and GVHD-free relapse-free survival (GRFS). Results: Group 1 and group 2 were not statistically different in regards to median age at allografting (54.1 vs. 56.1 years, p=0.51), median year of haplo transplantation (2018 vs. 2018, p=0.36), incidence of de novo AML (86.4% vs. 88.1%, p=0.63), Karnofsky equal or more than 90 (77.5% vs. 79.1%, p=0.70), and use of myeloablative conditioning (MAC) (44.7% vs. 48.5%, p=0.45). Patients in group 1 had a longer time from diagnosis to haplo-transplantation (5.3 vs. 4.9 months, p=0.03). In multivariate analysis, group 1 and group 2 did not differ in cumulative incidence of grade 2-4 acute GVHD (Hazard ratio (HR)=0.89 (95%CI=0.62-1.26), p=0.51) but group 1 had a significantly higher incidence of chronic (all grades) GVHD (HR=1.49 (95%CI=1.02-2.16), p=0.04). There was no difference in RI (HR=0.73 (95%CI=0.47-1.14), p=0.17), NRM (HR=1.25 (95%CI=0.78-2.02), p=0.36), LFS (HR=0.95 (95%CI=0.69-1.31), p=0.76), OS (HR=1.09 (95%CI=0.76-1.55), p=0.64) and GRFS (HR=1.07 (95%CI=0.81-1.42), p=0.64) between the groups. Presence of adverse cytogenetics was independently associated with higher RI (HR=1.90 (95%CI=1.20-2.99), p=0.006), inferior LFS (HR=1.59 (95%CI=1.15-2.19), p=0.005), inferior OS (HR=1.48 (95%CI=1.05-2.08), p=0.03), and worse GRFS (HR=1.54 (95%CI=1.17-2.04), p=0.002). Conclusion: Results show that patients undergoing haplo-transplantation with 4/8 (vs. 2-3/8) HLA mismatches have a higher incidence of chronic GVHD (all grades) without adversely affecting acute grade 2-4 GVHD, RI, LFS, OS and GRFS. Disclosures Labopin: Jazz Pharmaceuticals: Honoraria. Bazarbachi: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Hikma: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Astra Zeneca: Membership on an entity's Board of Directors or advisory committees. Blaise: Jazz Pharmaceuticals: Honoraria. McDonald: BioCryst Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees. Forcade: Novartis: Other: travel grant. Ciceri: IRCCS Ospedale San Raffaele: Current Employment. Mohty: Takeda: Honoraria; Astellas: Honoraria; Adaptive Biotechnologies: Honoraria; Novartis: Honoraria; Celgene: Honoraria, Research Funding; Bristol Myers Squibb: Honoraria; Sanofi: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Gilead: Honoraria; Jazz: Honoraria, Research Funding; Pfizer: Honoraria; Amgen: Honoraria.
OR25-05 Increased Overall Mortality and Cardiovascular Morbidity in Patients with Adrenal Incidentalomas and Autonomous Cortisol Secretion: Results of the ENS@T NAPACA-Outcome Study
Deutschbein, Timo , Dalmazi, Guido Di , Falhammar, Henrik , Tsagarakis, Stylianos , Ivocic, Miomira, Kaltsas, Grigorios, Pazaitou‐Panayiotou, Kalliopi , Loli, Paola , Yener, Abdullah Serkan, Langton, Katharina , Kocjan, Tomasz, Falhammar, Henrik , Reimondo, Giuseppe , Bancos, Irina , Newell‐Price, John , Kaštelan, Darko , Stigliano, Antonio , Scaroni, Carla Maria , Letizia, Claudio , Prete, Alessandro , Morelli, Valentina , Kaltsas, Grigorios, Hanzu, Felicia Alexandra , Shafigullina, Zulfiya R. , Zacharieva, Sabina , Terzolo, Massimo , Faßnacht, Martin

Mayo Clinic

Journal of the Endocrine Society | May 8, 2020 | Volume: 4 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaa046.1640 Get It

Abstract Objective. Several smaller studies on adrenal incidentalomas (AI) suggested an association between autonomous cortisol secretion (ACS) and mortality (Di Dalmazi Lancet Diabetes Endocrinol 2014, Debono J Clin Endocrinol Metab 2014, Patrova Endocrine 2017). However, a recent meta-analysis (9 studies, 1356 patients) could not confirm these findings (Elhassan Ann Intern Med 2019). Aim. To investigate the effects of ACS on mortality, prevalence of cardiovascular (CV) risk factors, and (CV) morbidity, in a representative cohort of AI. Design. Retrospective observational study conducted at 27 ENS@T centers from 15 countries. Methods. Inclusion criteria: AI diagnosed 1996-2015, 1 mg dexamethasone suppression test, follow-up (FU) of ≥36 months, known survival status. Exclusion criteria: clinically relevant adrenal hormone excess (i.e. Cushing’s syndrome, pheochromocytoma, primary hyperaldosteronism), known malignancy. Patient stratification: serum cortisol after dexamethasone (>5 µg/dl, ACS; 1.9-5 µg/dl, possible ACS (PACS); ≤1.8 µg/dl, non-functioning adenoma (NFA)). Definition of CV events (CVE): hospitalization due to myocardial infarction and related interventions (PTCA, surgical bypass), stroke, deep vein thrombosis, pulmonary embolism. Results. 3640 patients (57% NFA, 36% PACS, 7% ACS) were considered eligible: 64% females; median age 61 years (range 18-91); median FU 84 months (36-277) (distribution between subgroups n.s.). 352 patients died during FU. Age- and sex adjusted overall survival was significantly reduced in patients with PACS (HR 1.55; 95%CI 1.24-1.94) and ACS (1.84; 1.29-2.61). Prevalence of CV risk factors were significantly higher in PACS and ACS than in NFA (hypertension: 72, 73, 57%, p<0.0001; dyslipidemia: 42, 49, 35%, p<0.0001; diabetes: 22, 25, 17%, p<0.0001) When adjusted to relevant confounders (i.e. age, sex, CV risk factors), time to first CVE was shorter in PACS (HR 1.36; 1.07-1.73) and ACS (HR 1.62; 1.10-2.40) compared to NFA. Conclusion. PACS and ACS are associated with increased overall mortality and CV morbidity. However, to prove causality a large randomized intervention trial is required.
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission
Rashidi, Armin , Hamadani, Mehdi , Zhang, Mei-Jie , Wang, Hai-Lin, Abdel‐Azim, Hisham , Aljurf, Mahmoud , Assal, Amer , Bashey, Asad, Beitinjaneh, Amer , Bejanyan, Nelli , Bolaños‐Meade, Javier , Byrne, Michael , Cahn, Jean‐Yves, Cairo, Mitchell S. , Ciurea, Stefan O. , Copelan, Edward A. , Daly, Andrew , Diaz, Miguel-Angel, Farhadfar, Nosha , Ganguly, Siddhartha , Hahn, Theresa , Hashmi, Shahrukh K. , Hildebrandt, Gerhard , Holland, H. Kent, Hossain, Nasheed , Kanakry, Christopher G. , Kharfan‐Dabaja, Mohamed A. , Khera, Nandita , Martino, Rodrigo , Munker, Reinhold , Murthy, Hemant S. , Nakamura, Ryotaro , Nathan, Sunita , Palmisiano, Neil , Patel, Sagar S. , Pidala, Joseph, Olin, Rebecca L. , Olsson, Richard F. , Ringdén, Olle , Rizzieri, David A. , Rowe, Jacob M. , Savoie, Mary Lynn , Seo, Sachiko , Shaffer, Brian C. , Singh, Anurag K. , Solh, Melhem , Stockerl‐Goldstein, Keith , Verdonck, Leo F. , Wagner, John L. , Waller, Edmund K. , Litzow, Mark R. , Weisdorf, Dan, Saber, Wael , Weisdorf, Daniel J. , Wagner, John E. , Gale, Robert P , Hashmi, Shahrukh K , Hildebrandt, Gerhard C , Kharfan-Dabaja, Mohamed A., McGuirk, Joseph , Murthy, Hemant S , Nishihori, Taiga , Patel, Sagar , Olsson, Richard F , Ringden, Olov , Savoie, Mary Lynn , Wagner, John , Waller, Edmund K , Sandmaier, Brenda M , Litzow, Mark R. , Weisdorf, Dan , Hamadani, Mehdi , Assal, Amer , Martino, Rodrigo , Zhang, Mei‐Jie , Bajel, Ashish R. , Battiwalla, Minoo , Bhatt, Vijaya Raj , Cahn, Jean‐Yves , Cutler, Corey S. , Gale, Robert Peter , Grunwald, Michael R. , Koç, Yener , Lazarus, Hillard M. , Lee, Jong Wook , Maertens, Johan A. , McGuirk, Joseph P. , Nishihori, Taiga , Oran, Betül , Schultz, Kirk R. , Lima, Marcos de , Romee, Rizwan , Rashidi, Armin , Stockerl-Goldstein, Keith

Mayo Clinic

Blood Advances | June 14, 2019 | Volume: 3 | Issue: 12 | Pages: 1826-1836

10.1182/bloodadvances.2019000050 | PMID 31201170 Get It

Abstract HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling donor (MSD) is still considered the optimal donor. Using the Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) in first complete remission (CR1). Data from 1205 adult CR1 AML patients (2008-2015) were analyzed. A total of 336 patients underwent PT-Cy–based Haplo-HCT and 869 underwent MSD using calcineurin inhibitor–based graft-versus-host disease (GVHD) prophylaxis. The Haplo-HCT group included more reduced-intensity conditioning (65% vs 30%) and bone marrow grafts (62% vs 7%), consistent with current practice. In multivariable analysis, Haplo-HCT and MSD groups were not different with regard to overall survival (P = .15), leukemia-free survival (P = .50), nonrelapse mortality (P = .16), relapse (P = .90), or grade II-IV acute GVHD (P = .98). However, the Haplo-HCT group had a significantly lower rate of chronic GVHD (hazard ratio, 0.38; 95% confidence interval, 0.30-0.48; P < .001). Results of subgroup analyses by conditioning intensity and graft source suggested that the reduced incidence of chronic GVHD in Haplo-HCT is not limited to a specific graft source or conditioning intensity. Center effect and minimal residual disease–donor type interaction were not predictors of outcome. Our results indicate a lower rate of chronic GVHD after PT-Cy–based Haplo-HCT vs MSD using calcineurin inhibitor–based GVHD prophylaxis, but similar other outcomes, in patients with AML in CR1. Haplo-HCT is a viable alternative to MSD in these patients.